Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$305.96
+2.3%
$287.16
$146.20
▼
$333.30
$14.61B1.4927,461 shs105,963 shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$622.44
+2.1%
$604.41
$373.00
▼
$677.90
$17.41B1.18324,846 shs17,515 shs
Revvity Inc. stock logo
RVTY
Revvity
$155.64
+0.4%
$134.17
$81.22
▼
$166.25
$17.37B1.061.50 million shs168,462 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€19.23
-0.2%
€21.02
€12.89
▼
€27.99
€5.82B0.78498,880 shs38,415 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-0.83%-2.18%+7.64%+31.00%+75.16%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-1.64%+1.16%+3.81%+15.24%+15.64%
Revvity Inc. stock logo
RVTY
Revvity
-0.44%+1.14%+24.60%+39.17%+70.17%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
-1.12%-3.10%-8.52%-1.15%-17.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$305.96
+2.3%
$287.16
$146.20
▼
$333.30
$14.61B1.4927,461 shs105,963 shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$622.44
+2.1%
$604.41
$373.00
▼
$677.90
$17.41B1.18324,846 shs17,515 shs
Revvity Inc. stock logo
RVTY
Revvity
$155.64
+0.4%
$134.17
$81.22
▼
$166.25
$17.37B1.061.50 million shs168,462 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€19.23
-0.2%
€21.02
€12.89
▼
€27.99
€5.82B0.78498,880 shs38,415 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-0.83%-2.18%+7.64%+31.00%+75.16%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-1.64%+1.16%+3.81%+15.24%+15.64%
Revvity Inc. stock logo
RVTY
Revvity
-0.44%+1.14%+24.60%+39.17%+70.17%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
-1.12%-3.10%-8.52%-1.15%-17.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.88
Moderate Buy$302.331.02% Upside
Medpace Holdings, Inc. stock logo
MEDP
Medpace
2.23
Hold$607.73-0.35% Downside
Revvity Inc. stock logo
RVTY
Revvity
2.26
Hold$124.43-19.76% Downside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.75
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest STVN, RVTY, MEDP, and CRL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetBuy$130.00 ➝ $175.00
10/12/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
Boost Price TargetOverweight$300.00 ➝ $340.00
10/8/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
UpgradeBuy (B-) ➝ Buy (B)
10/8/2026
Revvity Inc. stock logo
RVTY
Revvity
UpgradeHold (C-) ➝ Hold (C)
10/7/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Boost Price TargetOutperform$665.00 ➝ $700.00
10/7/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetEqual Weight$115.00 ➝ $160.00
10/7/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Boost Price TargetEqual Weight$600.00 ➝ $625.00
10/7/2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
Initiated CoverageHold
10/5/2026
Revvity Inc. stock logo
RVTY
Revvity
Initiated CoverageOutperform
10/2/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
UpgradeHold ➝ Strong-Buy
9/30/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Initiated CoverageSell ➝ Neutral$405.00 ➝ $673.00
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.02B3.56$21.77 per share13.75$64.39 per share4.65
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.53B6.73$16.74 per share36.44$16.30 per share37.42
Revvity Inc. stock logo
RVTY
Revvity
$2.86B6.06$8.79 per share17.65$63.95 per share2.43
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.34B4.33€0.88 per share21.81€5.55 per share3.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-$144.34M-$4.85N/A23.682.83-5.96%15.75%6.51%11/4/2026 (Estimated)
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$451.12M$17.0635.7531.812.7717.67%110.15%24.84%10/21/2026 (Confirmed)
Revvity Inc. stock logo
RVTY
Revvity
$241.20M$2.1073.8526.282.838.16%8.34%5.01%11/3/2026 (Confirmed)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€158.21M€0.5634.2823.701.5710.99%10.43%6.16%N/A

Latest STVN, RVTY, MEDP, and CRL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.97N/AN/AN/A$959.99 millionN/A
11/3/2026Q3 2026
Revvity Inc. stock logo
RVTY
Revvity
$1.30N/AN/AN/A$694.74 millionN/A
10/21/2026Q3 2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$4.44N/AN/AN/A$714.47 millionN/A
8/5/2026Q2 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$2.77$3.02+$0.25-$0.03$980.53 million$1.00 billion
8/5/2026Q2 2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.15€0.14-€0.01€0.08N/A€302.00 million
8/4/2026Q2 2026
Revvity Inc. stock logo
RVTY
Revvity
$1.21$1.41+$0.20$0.47$702.96 million$729.69 million
7/22/2026Q2 2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$3.98$4.25+$0.27$4.25$689.51 million$707.33 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A
Revvity Inc. stock logo
RVTY
Revvity
$0.280.18%N/A13.33%N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years

Latest STVN, RVTY, MEDP, and CRL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2026
Revvity Inc. stock logo
RVTY
Revvity
quarterly$0.070.25%10/23/202610/23/202611/13/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.92
1.35
1.04
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.73
0.73
Revvity Inc. stock logo
RVTY
Revvity
0.36
1.80
1.50
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.21
1.61
1.08

Institutional Ownership

CompanyInstitutional Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
77.98%
Revvity Inc. stock logo
RVTY
Revvity
86.65%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
20.50%
Revvity Inc. stock logo
RVTY
Revvity
0.85%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
19,70047.74 million47.12 millionOptionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
6,20027.91 million22.19 millionOptionable
Revvity Inc. stock logo
RVTY
Revvity
11,000111.59 million110.64 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
6,010302.84 millionN/AOptionable

Recent News About These Companies

Morgan Stanley Gives a Hold Rating to Stevanato Group (STVN)
Stevanato Group (NYSE:STVN) Stock Falls 6.2% on Insider Selling
UBS Remains a Hold on Stevanato Group (STVN)
Stevanato Group (STVN) Receives a Hold from Morgan Stanley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$305.96 +6.94 (+2.32%)
As of 10:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Medpace stock logo

Medpace NASDAQ:MEDP

$622.44 +12.55 (+2.06%)
As of 10:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Revvity stock logo

Revvity NYSE:RVTY

$155.64 +0.56 (+0.36%)
As of 10:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€19.23 -0.04 (-0.18%)
As of 10:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.